✦ LIBER ✦

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

✍ Scribed by Hantschel, Oliver; Rix, Uwe; Superti-Furga, Giulio

Book ID: 115317280
Publisher: Informa plc
Year: 2008
Tongue: English
Weight: 441 KB
Volume: 49
Category: Article
ISSN: 1042-8194
DOI: 10.1080/10428190801896103

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The BCR/ABL-inhibitors imatinib, nilotin

The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

✍ Julia Salih; Julia Hilpert; Theresa Placke; Frank Grünebach; Alexander Steinle; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 937 KB

## Abstract In chronic myeloid leukemia (CML), BCR/ABL‐mediated oncogenic signaling can be targeted with the BCR/ABL‐inhibitors Imatinib, Nilotinib and Dasatinib. However, these agents may also affect anti‐tumor immunity. Here, we analyzed the effects of the 3 BCR/ABL‐inhibitors on natural killer (

Dasatinib treatment can overcome imatini

Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene

✍ Marta Barańska; Krzysztof Lewandowski; Michał Gniot; Małgorzata Iwoła; Maria Lew 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 70 KB

Drug interactions with the tyrosine kina

Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib

✍ Haouala, A.; Widmer, N.; Duchosal, M. A.; Montemurro, M.; Buclin, T.; Decosterd, 📂 Article 📅 2011 🏛 American Society of Hematology 🌐 English ⚖ 103 KB

An investigation of reversal of imatinib

An investigation of reversal of imatinib resistance in the Bcr-Abl positive imatinib-resistant cell line K562r by dasatinib, nilotinib, rapamycin and bortezomib

✍ H. XING; T. LIU; W. MENG; Y. GONG 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB

Clinical Pharmacokinetics of the BCR–ABL

Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib

✍ Tanaka, C; Yin, O Q P; Sethuraman, V; Smith, T; Wang, X; Grouss, K; Kantarjian, 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 202 KB

Overcoming imatinib resistance using Src

Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification

✍ Koji Morinaga; Takahiro Yamauchi; Shinya Kimura; Taira Maekawa; Takanori Ueda 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 600 KB

## Abstract Because imatinib (IM) resistance in chronic myeloid leukemia is primarily caused by the re‐establishment of Abl kinase, new inhibitors may be efficacious. We evaluated 3 new agents against 2 new K562 variants, IM‐R1 and IM‐R2 cells, which were developed having 7‐ and 27‐fold greater IM